ALTO-203 Fails to Primary Efficacy Endpoint in Phase 2 Major Depressive Disorder Trial

Retrieved on: 2025-06-27 18:36:14

Tags for this article:

Click the tags to see associated articles and topics

ALTO-203 Fails to Primary Efficacy Endpoint in Phase 2 Major Depressive Disorder Trial. View article details on hiswai:

Excerpt

Alto Neuroscience's ALTO-203 trial reveals mixed results, highlighting potential biomarkers for targeted depression treatment despite missing ...

Article found on: www.psychiatrictimes.com